ICAM1 and cancer: Although reported studies in the literature as well as our own observations all showed positive impact on cancer-specific drug delivery mediated by ICAM-1 [27,28,29], the ICAM-1-related adverse effects need to be further studied with different time frames, various doses, and function-specific assays.